BOSTON, March 3, 2026 – Linus Health will present new research at a leading global Alzheimer’s and Parkinson’s Diseases conference, revealing how advanced insights from digital cognitive assessments and personalized outcome measures may help transform how patients are identified for emerging therapies and how treatment impact is measured in ways that reflect patients’ personal priorities.
This research will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), taking place March 17-21, 2026, in Copenhagen, Denmark, and online. AD/PD convenes thousands of scientists, clinicians, and industry leaders to share the latest advances in basic science, translational research, clinical insights, and therapeutic innovation.
Linus Health will present three poster presentations highlighting the growing role of multimodal digital assessments in accelerating research across Alzheimer’s disease and related disorders.
Identifying Candidates for Disease-Modifying Therapies
All of the posters presented by Linus Health will be available for viewing from March 17 through midday on March 19. Poster locations will be listed in the official AD/PD™ 2026 program and onsite materials.
Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health, will present two posters:
#1367: Identifying Eligible Candidates for Alzheimer’s Disease Modifying Treatment with the Digital Clock and Recall (DCR™) demonstrates that a combination of two complementary multimodal, machine-learning models built from Linus Health DCR process metrics — the DCR Cognition Score and Amyloid Positivity Risk — shows a strong performance in identifying individuals in earlier symptomatic stages (mild cognitive impairment or mild dementia likely due to AD) who may be appropriate candidates for disease-modifying therapies.
#1925: Prediction of Plasma p-tau217 Status and Alzheimer’s Risk with the Remote Ready Digital Assessment of Cognition demonstrates how the Linus Health Digital Assessment of Cognition (DAC) delivers scalable, remote-ready predictions of p-tau217 status and biologically anchored cognitive phenotyping to support trial prescreening and community screening. With high classification accuracy and negative predictive value, the approach performs well as a front-end screener, helping prioritize confirmatory testing and reduce unnecessary biomarker testing for low-likelihood candidates.
“These findings underscore the growing role of digital, biologically anchored cognitive assessments in identifying and stratifying participants for Alzheimer’s research,” said Jannati. “By pairing high-resolution cognitive performance signals with biomarker risk estimation – such as amyloid-PET and plasma p-tau217 – we can more efficiently prioritize who should move to confirmatory testing, reduce unnecessary procedures, and accelerate recruitment while maintaining scientific rigor.”
Elevating Participant Priorities
Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, will present new data exploring how culturally responsive, person-specific outcome measures can be scaled across international Alzheimer’s research settings.
#2179: A Feasibility Study to Assess the Applicability and User Acceptance of the Electronic Person Specific Outcome Measures (ePSOM) in a Japanese Memory Clinic Population. ePSOM is a digital tool that captures what matters most to patients in their daily lives and measures their confidence in maintaining those priorities over time. The study assesses the feasibility and acceptability of the ePSOM tool among Japanese patients with early symptomatic Alzheimer’s disease and explores how individual patient priorities can be incorporated into study endpoints in different cultural settings.
The research builds on prior work in the United Kingdom and the United States and advances understanding of how personalized, patient-centered evaluations can be implemented at scale in international trials.
“As new treatments for Alzheimer’s disease emerge, it is essential that study endpoints incorporate the participant perspective of what matters most across cultures,” said Saunders. “Our results support the feasibility of implementing individualized outcome measures in diverse clinical environments across multiple countries.”
Advancing a Multimodal Approach to Neurodegenerative Research
In addition to the new research, Linus Health will emphasize at AD/PD its broader multimodal platform, which integrates cognitive, speech, and motor assessments to support research across neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease.
By combining data from multiple domains, Linus Health solutions enable life sciences organizations to efficiently identify potential participants for clinical trials of new brain health therapies. The platform also enables researchers and clinicians to develop composite digital endpoints that support earlier detection, more precise stratification, and longitudinal tracking across disease stages.
Conference attendees are invited to set up time to meet with the Linus Health team onsite in Copenhagen.
About Linus Health
Linus Health is a Boston-based digital health company focused on transforming brain health for people around the world. By advancing how we detect and address cognitive and brain disorders leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence, the company’s goal is to enable a future where people can live longer, healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a practical means of enabling early detection, empowers providers and researchers with actionable insights, and supports individuals with personalized action plans. The company partners with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. To learn more about our practical solutions for proactive brain health®, visit www.linushealth.com or follow Linus Health on LinkedIn.
Media Contact:
Tara Stultz (Supreme Communications for Linus Health)
tstultz@acmarketingpr.com